Continuing Pneumococcal Vaccination After Gavi Transition in Kenya at Full Price is Cost-effective and Could Save Thousands of Lives

This news release was originally published on EurekAlert. Below is an excerpt from the news release.

Co-led by the London School of Hygiene & Tropical Medicine and the KEMRI-Wellcome Trust Research Program, the Pneumococcal Conjugate Vaccine Impact Study estimated that continuing the vaccine beyond 2022 would prevent – in the first ten years – more than 100,000 children and adults from contracting pneumococcal disease and save the lives of 14,000 children and adults who would otherwise have died.

The cost per year of healthy life saved (US $153) was considerably less than Kenya’s annual gross domestic product (GDP) per person (US $1,790 in 2018), which meets – and far exceeds – the World Health Organization (WHO) GDP-related threshold for ‘very cost-effective’ health interventions.

The researchers say this study offers important evidence for policymakers at what is a crucial time for countries that have to decide whether to continue vaccine programs that have benefited from Gavi’s subsidy of the cost of vaccines once their economies grow and Gavi support diminishes.

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Submissions Open for Special Issue of Vaccines on Estimating Vaccines’ Value and Impact

Estimating the value and public health impact of vaccines is critical to ensure evidence-based policy decision making in nearly all stages, from vaccine development to the introduction/implementation of vaccines in low-resource settings. To foster public health equity, as well as estimate value to local and national economies, concerted efforts are needed to increase the understanding … Continued

COVAX Application Materials for AMC Eligible Economies Now Available

The COVAX Facility released the application and guidance documents (“application package”) for eligible economies to (i) confirm participation in the COVAX Facility and (ii) request support as part of COVAX. This comprises COVID-19 vaccines, as well as Cold Chain Equipment and Technical Assistance needed to prepare for the delivery of COVID-19 vaccines.  All 92 AMC Eligible … Continued

New Evidence Shows Investments in Vaccination Produce Even Greater Returns than Previously Thought

This article originally appeared on Gavi’s website.  The Decade of Vaccine Economics (DoVE) Project, carried out by the Johns Hopkins Bloomberg School of Public Health’s International Vaccine Access Center (IVAC) for nearly ten years, has computed the return-on-investment for vaccines preventing ten infectious diseases in 94 low- and middle-income countries, including 73 countries that have received support from … Continued